

Company Overview (LSE: SNG)

Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta (IFN- β) candidate (SNG001) as potentially the first host directed broad-spectrum antiviral treatment delivered directly into the lungs.

Pioneers of using ex vivo models, which use cells collected from patients with respiratory disease, the company is exploring the use of SNG001 in other serious viral lung infections. Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in.

Founded in 2003 by Professor Sir Stephen Holgate, Professor Ratko Djukanovic and Professor Donna Davies, the company embarked on research to better understand why some lungs are better able to defend against viral infections than others.

In pursuit of this aim, it was discovered that a deficiency of IFN- β in the lungs could explain the enhanced susceptibility of at-risk patient groups to developing severe lung disease during respiratory viral infections.

As a result of this pioneering research, Synairgen is now investigating inhaled IFN- β as a broad-spectrum antiviral for severe viral lung infections.

Synairgen is
quoted on the
London Stock
Exchange's AIM

LSE: SNG

World-class academic founders



Professor Sir Stephen Holgate,
CBE, FMedSci
MRC Clinical Professor of
Immunopharmacology



Professor Ratko Djukanovic,
MD, DM, FRCP
Professor of Medicine, University of
Southampton



Professor Donna E Davies,
PhD FMedSci
Clinical and Experimental Sciences
Faculty of Medicine
University of Southampton



*Why do I study
Lung Disease?*

*The average person
takes around 20,000
breaths every day...
imagine fighting for
every one of them...*

Professor Donna Davies,
Synairgen co-founder

Our expertise

- Lung defence research
- Investigation of pandemic-ready respiratory therapeutic candidates

Awards and Recognition

- 2021 Shortlisted
'Clinical Advance of the Year'
Scrip Awards
- 2021 Shortlisted
'Breakthrough of the Year'
European Mediscience Awards
- 2021 Shortlisted
'CEO of the Year'
European Mediscience Awards

Synairgen Leadership

Management Team



Richard Marsden
CEO



Dr. Phillip Monk
Chief Scientific Officer



John Ward
Chief Financial Officer



Gareth Waters
Chief Regulatory Officer



Richard Hennings
Chief Commercial Officer



Brooke Clarke
SVP Head of
Communications
and Corporate Affairs



Richard Francis
SVP Head of CMC




Jody Brookes
SVP Head of Clinical
Operations



Helen Gearing
SVP Finance

Key company milestones

2003	June	Company founded by Professor Sir Stephen Holgate, Professor Ratko Djukanovic and Professor Donna Davies
2004	October	Listed on London Stock Exchange (AIM)
2009	September	IFN- β US patent granted
2010	April	Began SG005, a Phase 2 trial to evaluate the treatment of exacerbations of asthma caused by respiratory viruses
	May	IFN- β European patent granted
2011	July	IFN- β Japanese patent granted
2012	April	Announced positive data from Phase 2 trial investigating the potential for SNG001 to protect asthmatics from respiratory virus infections
2018	February	Initiated SG015, a two-part Phase 2 trial to evaluate the potential of SNG001 in COPD
2020	March	Obtained MRHA approval to conduct trial of SNG001 in COVID-19 patients; commenced dosing in Phase 2 COVID-19 trial (SG016)
	July	Announced positive results from SG016 in hospitalised COVID-19 patients
	September	Shared positive data from interim analysis of SG015 trial in COPD patients Launched Managed Access Programme for SNG001 in partnership with Clinigen
	November	Results of SG016 hospital trial published in <i>Lancet Respiratory Medicine</i>
2021	January	Commenced dosing in 17-country Phase 3 SPRINTER study (SG018) for treatment of COVID-19 in hospitalised patients SNG001 included in US National Institutes of Health's ACTIV-2 trial in non-hospitalised patients
	February	First patient dosed in ACTIV-2 trial with SNG001
	April	Released results of SG016 trials in home-based COVID-19 patients
	May	Announced results of <i>in vitro</i> studies that shows potent antiviral activities of SNG001 against SARS-CoV-2 variants Alpha and Beta
	October	SNG001 graduated to Phase 3 in the ACTIV-2 trial
	November	Completed recruitment in the Phase 3 SPRINTER study (SG018) of SNG001 in hospitalised COVID-19 patients



Contacts:

Communications, Corporate Affairs
& Investor relations

Brooke Clarke

brooke.clarke@synairgen.com

Business Development

Richard Hennings

richard.hennings@synairgen.com

Human Resources

Sue Grenfell

hr@synairgen.com



For more information, please visit
www.synairgen.com